These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 1507517)

  • 1. Antiarrhythmic effects of MS-551, a new class III antiarrhythmic agent, on canine models of ventricular arrhythmia.
    Kamiya J; Ishii M; Katakami T
    Jpn J Pharmacol; 1992 Feb; 58(2):107-15. PubMed ID: 1507517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of MS-551, a new class III antiarrhythmic drug, on programmed stimulation-induced ventricular arrhythmias, electrophysiology, and hemodynamics in a canine myocardial infarction model.
    Kondoh K; Hashimoto H; Nishiyama H; Umemura K; Ozaki T; Uematsu T; Nakashima M
    J Cardiovasc Pharmacol; 1994 Apr; 23(4):674-80. PubMed ID: 7516022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiarrhythmic and proarrhythmic effects of sematilide in canine ventricular arrhythmia models.
    Xue YX; Eto K; Akie Y; Hashimoto K
    Jpn J Pharmacol; 1996 Feb; 70(2):129-38. PubMed ID: 8866750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of dofetilide, a class III antiarrhythmic drug, on various ventricular arrhythmias in dogs.
    Chen J; Xue Y; Eto K; Ni C; Hashimoto K
    J Cardiovasc Pharmacol; 1996 Oct; 28(4):576-84. PubMed ID: 8891885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of an antiarrhythmic drug A-2545 on canine ventricular arrhythmia models; comparison with mexiletine and flecainide.
    Xue YX; Arita J; Aye NN; Hashimoto K
    Naunyn Schmiedebergs Arch Pharmacol; 1998 Dec; 358(6):649-56. PubMed ID: 9879724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The antiarrhythmic actions of intravenous and oral UM424 in postinfarction canine myocardium.
    Gibson JK; Patterson E; Lucchesi BR
    J Cardiovasc Pharmacol; 1985; 7(2):211-8. PubMed ID: 2581070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protection against programmed electrical stimulation-induced ventricular tachycardia and sudden cardiac death by NE-10064, a class III antiarrhythmic drug.
    Black SC; Butterfield JL; Lucchesi BR
    J Cardiovasc Pharmacol; 1993 Dec; 22(6):810-8. PubMed ID: 7509898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiarrhythmic effects of a novel class III drug, KCB-328, on canine ventricular arrhythmia models.
    Xue Y; Tanabe S; Nabuchi Y; Hashimoto K
    J Cardiovasc Pharmacol; 1998 Aug; 32(2):239-47. PubMed ID: 9700986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiarrhythmic and electrophysiologic effects of MDL 11,939, a novel class III antiarrhythmic agent in anesthetized dogs.
    Koerner JE; Dage RC
    J Cardiovasc Pharmacol; 1990 Sep; 16(3):383-93. PubMed ID: 1700208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and plasma concentrations of SC-36602 in canine models of ventricular arrhythmia.
    Garthwaite SM; Hatley FR; Frederick LG; Cook C
    J Cardiovasc Pharmacol; 1989 Feb; 13(2):218-26. PubMed ID: 2468949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiarrhythmic efficacy of a new class III agent, UK-68,798, during chronic myocardial infarction: evaluation using three-dimensional mapping.
    Zuanetti G; Corr PB
    J Pharmacol Exp Ther; 1991 Jan; 256(1):325-34. PubMed ID: 1988663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Electrophysiological effects of MS-551, a new class III agent: comparison with dl-sotalol in dogs.
    Sen L; Cui G; Sakaguchi Y; Singh BN
    J Pharmacol Exp Ther; 1998 May; 285(2):687-94. PubMed ID: 9580614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: experimental profile of BRL-32872.
    Bril A; Gout B; Bonhomme M; Landais L; Faivre JF; Linee P; Poyser RH; Ruffolo RR
    J Pharmacol Exp Ther; 1996 Feb; 276(2):637-46. PubMed ID: 8632331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of the new class III antiarrhythmic drug MS-551 and d-sotalol on canine coronary ligation-reperfusion ventricular arrhythmias.
    Hashimoto K; Haruno A; Hirasawa A; Awaji T; Xue Y; Wu Z
    Jpn J Pharmacol; 1995 May; 68(1):1-9. PubMed ID: 7494370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Electrophysiological, rate dependent, and autonomic effects of the class III antiarrhythmic almokalant after myocardial infarction in the pig.
    Tuininga YS; De Langen CD; Crijns HJ; Wiesfeld AC; Mook PH; Bel KJ; Lie KI
    Pacing Clin Electrophysiol; 1996 May; 19(5):802-10. PubMed ID: 8734747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiarrhythmic effect of a new class 1 antiarrhythmic drug, nicainoprol, on canine ventricular arrhythmias.
    Hashimoto K; Akiyama K; Mitsuhashi H
    Jpn J Pharmacol; 1989 Feb; 49(2):245-54. PubMed ID: 2733262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacological and clinical profile of nifekalant (shinbit injection), a class III antiarrhythmic drug].
    Oyabe A; Sano H
    Nihon Yakurigaku Zasshi; 2002 Feb; 119(2):103-9. PubMed ID: 11862758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MS-551 and KCB-328, two class III drugs aggravated adrenaline-induced arrhythmias.
    Xue Y; Yamada C; Aye NN; Hashimoto K
    Br J Pharmacol; 1998 Aug; 124(8):1712-8. PubMed ID: 9756388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metoprolol versus sotalol in the treatment of sustained ventricular tachycardia.
    Antz M; Cappato R; Kuck KH
    J Cardiovasc Pharmacol; 1995 Oct; 26(4):627-35. PubMed ID: 8569226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MS-551 protects against ventricular fibrillation in a chronic canine model of sudden cardiac death.
    Friedrichs GS; Chi L; Gralinski MR; Black SC; Basler GC; Mu DX; Pewitt SR; Johnson CR; Lucchesi BR
    J Cardiovasc Pharmacol; 1995 Feb; 25(2):314-23. PubMed ID: 7752658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.